Federal Trade Commission – Caremark Agrees To Settle FTC Antitrust Case

The FTC secured an $8.5 billion settlement with Caremark, requiring the pharmacy benefit manager to overhaul rebate-driven practices that artificially inflated insulin prices. The settlement delinks PBM fees from list prices, mandates transparency, and allows plan sponsors to shift to cost-plus reimbursement models.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.